Cellerant Therapeutics Inc. has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services.   The award supports continued development of CLT-008, an allogeneic, cell-based therapy for the treatment of hematopoietic sub-syndrome of Acute Radiation Syndrome (ARS). Previously, $116.4 million was committed under a...